Alnylam Pharmaceuticals Inc ALNY:NASDAQ (Common Stock)

LastDaily Change / % ChangeDividend YieldVolumeAvg Volume (10 day)
115.57 0.00   0.00%--809,807972.7K
Market data is delayed by at least 15 minutes.
Summary chart showing the current equity's performance of over the past 1 days
  • Advanced Charts
  • Embed the above chart in your blog or website

    Customize, copy, and then paste the generated code into your website.

Previous close 10/23/2017 (03:59 PM 10/23/2017 Eastern Standard Time)

Latest News Headlines for Alnylam Pharmaceuticals Inc

Alnylam and Collaborators to Present APOLLO Phase 3 Study Results at 1(st) European ATTR Amyloidosis Meeting for Patients and Doctors

-- Company to Host Conference Call on Thursday, November 2, 2017, at 12:30 pm ET to Discuss Results -- CAMBRIDGE, Mass.--(BUSINESS WIRE)--October 20, 2017-- Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, announced today that the results of the APOLLO Phase 3 study of patisiran in hereditary ATTR (hATTR) amyloidosis patients with polyneuropathy, as well as additional posters on patisiran and hATTR amyloidosis, will be presented at the 1(st) European ATTR Amyloidosis Meeting for Patients and Doctors being held November 2-3, 2017 in Paris, France.

Alnylam and Vir Form Strategic Alliance to Advance RNAi Therapeutics for Infectious Diseases

-- Agreement Includes Investigational RNAi Therapeutic Program for Hepatitis B Virus Infection and Discovery Collaboration on Additional Development Candidates for Treatment of Infectious Diseases --

View more recent headlines

Peers Information HelpALNY Alnylam Pharmaceuticals Inc vs. Peers

Alnylam Pharmaceuticals Inc
bluebird bio Inc
Exelixis, Inc.
Seattle Genetics, Inc.
Alnylam Pharmaceuticals Inc
bluebird bio Inc
Exelixis, Inc.
Seattle Genetics, Inc.
Alnylam Pharmaceuticals Inc
bluebird bio Inc
Exelixis, Inc.
Seattle Genetics, Inc.
Compare these stocks

Latest Annual and Quarterly SEC Filings

More Filings

This report contains detailed information about the company's business finances and management.


Quarterly reports contain financial statement, a discussion from management and a list of company events (stock splits, acquisitions, etc.)

Company Background

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses on three Strategic Therapeutic Areas (STArs): Genetic Medicines, with multiple product candidates for the treatment of rare diseases; Cardio-Metabolic Diseases, with product candidates directed toward genetically validated, liver-expressed disease targets for unmet needs in cardiovascular and metabolic diseases, and Hepatic Infectious Diseases, with product candidates designed to address the global health challenges of hepatic infectious diseases, beginning with hepatitis B and hepatitis D viral infections. The Company's lead product, Patisiran, is formulated utilizing lipid nanoparticles (LNPs).


collapse, right-facing arrow indicating collapsed view of sectionOverview

A table providing an overview of the stock
Bid | Size-- | --
Ask | Size-- | --
Price Open114.66
Previous Close115.57
Day High116.455
Day Low112.95
52 Week High10/12/2017 | 126.16
52 Week Low11/3/2016 | 31.38
% Off 52 Week High-8.39%
% Off 52 Week Low268.29%
Beta (5 Yr)3.0
Volatility Avg10/23/2017 | 76.32
10-Day Avg. Volume972,710
Market data is delayed by at least 15 minutes.

expand, down-facing arrow indicating expanded view of sectionFundamentals

A table providing the fundamentals of the stock
EPS (TTM)6/30/2017 | -5.12
P/E Ratio6/30/2017 | --
Market CapLarge Cap | 10.60B
Shares Outstanding91.73M

collapse, right-facing arrow indicating collapsed view of sectionDividends

A table providing information about the dividends of the stock
Dividend Yield--
Dividend Announcement--
Date of Record--
Payable-- - --
Payable Date--

collapse, right-facing arrow indicating collapsed view of sectionShare Statistics

A table providing statistics about shares of the stock
Shares Short6.95M
Short Ratio2.0
Short % of Float9.08%
As of 9/29/2017
The performance data quoted represents past performance. Past performance does not guarantee future results. Current performance may be lower or higher than the performance quoted. Investment return and principal value of an investment will fluctuate and when redeemed, the investment may be worth more or less than their original cost.
The research, tools, and information provided will not include every security available to the public.